Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a biological pathway that helps explain why some bladder cancers do not respond well ...

NCCN now recognizes BCG-unresponsive papillary-only NMIBC as eligible for nogapendekin plus BCG, broadening access beyond the ...

NCCN now includes Anktiva plus BCG for BCG-unresponsive papillary-only NMIBC, acknowledging an unmet need in patients without CIS who have limited post-BCG options. Radical cystectomy remains ...

Immunotherapy uses the power of your immune system to fight your cancer. One type of immunotherapy is called an immune checkpoint inhibitor. Your immune system has built-in checkpoints that help it ...

Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting patient impact. At the 2026 ASCO GU meeting, experts gathered to share the ...

The phase 2, single-arm INDIBLADE trial assessed induction ipilimumab plus nivolumab followed by CRT in patients with MIBC.

ImmunityBio Inc. IBRX shares are up Tuesday following the announcement that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer ...

A prospective, multicenter phase 2 trial evaluated the safety of neoadjuvant radiation plus immunotherapy before radical cystectomy for bladder cancer.

ImmunityBio Inc. (NASDAQ:IBRX) is one of the most buzzing stocks to buy with the highest upside potential. On March 9, ...

Another immunotherapy has been approved for use in urothelial cancer, the most common type of bladder cancer, in the United States. Avelumab (Bavencio, EMD Serono INc), which is a programmed cell ...

In a multi-institutional study published in Science Direct, researchers revealed that testing urine-based tumor DNA (utDNA) can help predict which bladder cancer patients are at higher risk for ...

ImmunityBio (NasdaqGS:IBRX) completed enrollment early in its pivotal Phase 2 bladder cancer trial for ANKTIVA. Interim analysis showed a statistically significant improvement in complete response ...